Palvella Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Accrued Liabilities of $650 for the 16-month period ending 2014-09-30, per its 10-Q filed 2014-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2014-12-12
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2014-03-31 was $1.25K.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2013-12-31 was $1.25K.
- Palvella Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2013-09-30 was $1.25K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 7 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 10 month | Increase (Decrease) in Accrued Liabilities 16 month |
|---|---|---|---|---|---|---|
| 2014-09-30 | $650.00 10-Q · filed 2014-11-13 | |||||
| 2014-03-31 | $1.25K 10-Q · filed 2014-06-02 | $2.50K derived: sum of 2 quarters · filed 2014-06-02 | $2.50K 10-Q · filed 2014-06-02 | $2.50K 10-Q · filed 2014-06-02 | ||
| 2013-12-31 | $1.25K 10-Q · filed 2014-05-14 | $1.25K 10-Q · filed 2014-05-14 | $1.25K 10-Q · filed 2014-05-14 | |||
| 2013-09-30 | $1.25K 10-Q · filed 2014-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |